Germany ranks fourth globally in biopharmaceuticals, with over 650 biotechnology companies. Its collaboration among industry, government, and research sectors, along with bioregions, propels the sector forward. The increasing prevalence of chronic diseases and an aging population have boosted demand for biologic drugs, leading to an 8% annual growth in prescriptions. Investments by Boehringer Ingelheim and new facilities by WuXi, Chime, and AGC Biologics underscore Germany’s appeal, thanks to its strategic location, skilled workforce, advanced infrastructure, and government incentives.

Biologics Manufacturing Germany 2024 will delve into advancements in biomanufacturing and examine how rising operational complexity and uncertainty impact long-term decision-making. Topics will include risk mitigation, regulatory changes, and CMO partner selection, especially in light of automation, AI, and sustainability. These discussions are crucial for stakeholders in the biologics manufacturing industry, providing valuable insights on navigating challenges and making informed decisions in a complex and dynamic environment.

What to anticipate at Biologics Manufacturing Germany 2024?

10+ Roundtables on Optimising Biomanufacturing in Germany

Network with 120 Leading German Biopharma Companies

Exclusive German CMO Case Studies